| Kendal Harrod, LMFT | |
|
104 Borders Way Ste 500, Warner Robins, GA 31088-8967 | |
| (478) 352-0422 | |
| Not Available |
| Full Name | Kendal Harrod |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 104 Borders Way Ste 500, Warner Robins, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386331767 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | MFT002036 (Georgia) | Primary |
| Entity Name | Georgia Behavioral Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861931172 PECOS PAC ID: 3072845692 Enrollment ID: O20191031002699 |
News Archive
The inventor of a ground-breaking COVID-19 test described his ‘eureka moment' when he realised he could adapt existing tech to create a rapid virus test.
Researchers at Oregon Health & Science University's School of Dentistry have made an important connection between a molecule critical to nerve cells and high blood pressure. Production of the molecule Brain-Derived Neurotrophic Factor (BDNF) appears to increase dramatically in blood pressure-sensing nerve cells during hypertension.
COVID-19 stressors are negatively impacting resettled refugees' mental health, a new study by UNSW Sydney psychologists in partnership with Australian Red Cross, Settlement Services International and Phoenix Australia at the University of Melbourne has shown.
Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the chronic management of urea cycle disorders. Hyperion recently completed its phase III trial which was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The Company plans to announce results from that trial later this year.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kendal Harrod, LMFT Po Box 6446, Americus, GA 31709-6446 Ph: (229) 938-9031 | Kendal Harrod, LMFT 104 Borders Way Ste 500, Warner Robins, GA 31088-8967 Ph: (478) 352-0422 |
News Archive
The inventor of a ground-breaking COVID-19 test described his ‘eureka moment' when he realised he could adapt existing tech to create a rapid virus test.
Researchers at Oregon Health & Science University's School of Dentistry have made an important connection between a molecule critical to nerve cells and high blood pressure. Production of the molecule Brain-Derived Neurotrophic Factor (BDNF) appears to increase dramatically in blood pressure-sensing nerve cells during hypertension.
COVID-19 stressors are negatively impacting resettled refugees' mental health, a new study by UNSW Sydney psychologists in partnership with Australian Red Cross, Settlement Services International and Phoenix Australia at the University of Melbourne has shown.
Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the chronic management of urea cycle disorders. Hyperion recently completed its phase III trial which was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The Company plans to announce results from that trial later this year.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.
› Verified 5 days ago
Scott Justin Glenn, L.M.F.T. Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 109 Osigian Blvd, Warner Robins, GA 31088 Phone: 478-449-1475 | |
Carleen Mays Forbes, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 320 Oakview Square, Warner Robins, GA 31093 Phone: 478-972-0230 Fax: 479-328-0635 | |
Patti S Mccurdy, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 603 Russell Pkwy Ste B, Warner Robins, GA 31088 Phone: 478-396-8388 | |
Mrs. Joyce Mack-leonard, MFS LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 402 Corder Rd, Suite 200, Warner Robins, GA 31088 Phone: 478-929-4962 Fax: 478-928-4960 | |
Mrs. Beth Anne Grant, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 300 S Houston Lake Rd, Warner Robins, GA 31088 Phone: 478-953-0709 Fax: 478-953-0709 | |
Kathryn Mcgehee, LMFT Couples Therapy Medicare: Medicare Enrolled Practice Location: 501 Osigian Blvd, Warner Robins, GA 31088 Phone: 478-741-1464 Fax: 478-742-1883 |